Jacobs Levy Equity Management
RETA

Jacobs Levy Equity Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Jacobs Levy Equity Management’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-95,726
Closed -$3.64M – 1090
2022
Q4 		$3.64M Sell
95,726
-22,247
-19% -$766K 0.02% 451
2022
Q3 		$2.96M Buy
+117,973
New +$3.27M 0.02% 485

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobs Levy Equity Management's RETA Position: Q1 2023 in Review

Jacobs Levy Equity Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2023, closing a stake of 95,726 shares — an estimated $3.64M sold.

Jacobs Levy Equity Management first reported a position in RETA in Q3 2022 and held it in 2 quarters. The position peaked at $3.64M in Q4 2022. 205 funds tracked by Wall St. Rank hold RETA as of Q1 2023.

  • Jacobs Levy Equity Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 95,726 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2023, an estimated $3.64M.
  • Jacobs Levy Equity Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2022 and held it in 2 quarters.
  • Jacobs Levy Equity Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $3.64M in Q4 2022.
  • 205 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2023.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2023, filed 15 May 2023.